A systematic review of existing data on long-term lithium therapy: Neuroprotective or neurotoxic?

International Journal of Neuropsychopharmacology

Volumn 11, Issue 2, 2008, Pages 269-287

  Fountoulakis, Konstantinos N ^a,b,e   Vieta, Eduard ^c   Bouras, Constantin ^b   Notaridis, Grigorios ^b   Giannakopoulos, Panteleimon ^b   Kaprinis, George ^a   Akiskal, Hagop ^d  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NONE   (Greece)

Author keywords

Lithium; Long term treatment; Neuroprotection; Neurotoxicity

Indexed keywords

AMITRIPTYLINE; ATROPINE; BACLOFEN; CAMPTOTHECIN; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; DIAZEPAM; DIZOCILPINE; ETOPOSIDE; HALOPERIDOL; KETAMINE; LITHIUM; LOXAPINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; OUABAIN; PENTOBARBITAL; PHENYTOIN; PILOCARPINE; QUINOLINIC ACID; SCOPOLAMINE; TACRINE; THIORIDAZINE; TOPIRAMATE; UNINDEXED DRUG; VALINOMYCIN; VALPROIC ACID;

BIPOLAR DISORDER; BRAIN ISCHEMIA; CREUTZFELDT JAKOB DISEASE; DELIRIUM; DRUG BLOOD LEVEL; DRUG MECHANISM; EPILEPSY; HUMAN; LONG TERM CARE; MONOTHERAPY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA;

ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; LITHIUM COMPOUNDS; NEURONS; NEUROPROTECTIVE AGENTS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT;

EID: 38949167104     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145707007821     Document Type: Review

References (237)

1. Addonizio G (1985). Rapid induction of extrapyramidal side effects with combined use of lithium and neuroleptics. Journal of Clinical Psychopharmacology 5, 296-298.
2. Addy RO, Foliart RH, Saran AS, Schubert DS (1986). EEG observations during combined haloperidol-lithium treatment. Biological Psychiatry 21, 170-176.
3. Adityanjee (1989). The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT). Pharmacopsychiatry 22, 81-83.
4. Adityanjee, Munshi KR, Thampy A (2005). The syndrome of irreversible lithium-effectuated neurotoxicity. Clinical Neuropharmacology 28, 38-49.
5. Akiskal HS (1999). Affective disorders. Merck Manual of diagnosis and Therapy (pp. 1525-1544). Rathaway, NJ: Merck Sharp and Dohme Research Laboratories.
6. Akpaffiong MJ (1992). Risk factors for neuroleptic malignant syndrome. Journal of the National Medical Assocication 84, 800-802.
7. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J (1999). Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Letters 453, 260-264.
8. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J (2002). Regulation of tau phosphorylation and protection against betaamyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disorder 4, 153-165.
9. Ananth J, Ghadirian AM, Engelsmann F (1987). Lithium and memory: a review. Canadian Journal of Psychiatry 32, 312-316.
10. Arendt T, Lehmann K, Seeger G, Gartner U (1999). Synergistic effects of tetrahydroaminoacridine and lithium on cholinergic function after excitotoxic basal forebrain lesions in rat. Pharmacopsychiatry 32, 242-247.
11. Arya DK (1996). Lithium-induced neurotoxicity at serum lithium levels within the therapeutic range. Australian and New Zealand Journal of Psychiatry 30, 871-873.
12. Austin LS, Arana GW, Melvin JA (1990). Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients. Journal of Clinical Psychiatry 51, 344-345.
13. Axelsson R, Nilsson A (1991). On the pathogenesis of abnormal involuntary movements in lithium-treated patients with major affective disorder. European Archives of Psychiatry and Clinical Neuroscience 241, 1-7.
14. Bagetta G, Paoletti AM, Leta A, Del Duca C, Nistico R, Rotiroti D, Corasaniti MT (2002). Abnormal expression of neuronal nitric oxide synthase triggers limbic seizures and hippocampal damage in rat. Biochemical and Biophysical Research Communications 291, 255-260.
15. Baldessarini RJ, Tondo L, Hennen J (2003). Lithium treatment and suicide risk in major affective disorders: update and new findings. Journal of Clinical Psychiatry 64 (Suppl. 5), 44-52.
16. Ban TA (1978). Adverse effects in maintenance therapy. International Pharmacopsychiatry 13, 217-229.
17. Bauer M, Alda M, Priller J, Young LT (2003). Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry 36 (Suppl. 3), S250-254.
18. Bech P (2006). The full story of lithium. A tribute to Mogens Schou (1918-2005). Psychotherapy and Psychosomatics 75, 265-269.
19. Bech P, Vendsborg PB, Rafaelsen OJ (1976). Lithium maintenance treatment of manic-melancholic patients: its role in the daily routine. Acta Psychiatrica Scandinavica 53, 70-81.
20. Beitman BD (1978). Tardive dyskinesia reinduced by lithium carbonate. American Journal of Psychiatry 135, 1229-1230.
21. Bell AJ, Cole A, Eccleston D, Ferrier IN (1993). Lithium neurotoxicity at normal therapeutic levels. British Journal of Psychiatry 162, 689-692.
22. Beurel E, Kornprobst M, Blivet-Van Eggelpoel MJ, Ruiz-Ruiz C, Cadoret A, Capeau J, Desbois-Mouthon C (2004). GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression. Experimental Cell Research 300, 354-364.
23. Beyer JL, Kuchibhatla M, Payne ME, Moo-Young M, Cassidy F, Macfall J, Krishnan KR (2004). Hippocampal volume measurement in older adults with Bipolar Disorder. American Journal of Geriatric Psychiatry 12, 613-620.
24. Bijur GN, De Sarno P, Jope RS (2000). Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. Journal of Biological Chemistry 275, 7583-7590.
25. Bocchetta A (2003). Psychotic mania in glucose-6-phosphate- dehydrogenase-deficient subjects. Annals of General Hospital Psychiatry 2, 6.
26. Bown CD, Wang JF, Young LT (2003). Attenuation of Nmethyl-D-aspartate-mediated cytoplasmic vacuolization in primary rat hippocampal neurons by mood stabilizers. Neuroscience 117, 949-955.
27. Brambilla P, Stanley JA, Sassi RB, Nicoletti MA, Mallinger AG, Keshavan MS, Soares JC (2004). 1H MRS study of dorsolateral prefrontal cortex in healthy individuals before and after lithium administration. Neuropsychopharmacology 29, 1918-1924.
28. Broussolle E, Setiey A, Moene Y, Trielett M, Chazot G (1989). Reversible Creutzfeldt-Jakob like syndrome induced by lithium plus levodopa treatment. Journal of Neurology Neurosurgery and Psychiatry 52, 686-687.
29. Brown AS, Rosen J (1992). Lithium-induced delirium with therapeutic serum lithium levels: a case report. Journal of Geriatric Psychiatry and Neurology 5, 53-55.
30. Buchanan DS (1978). Iatrogenic causes of neurologic disorders: part 2. Drug-related dysfunctions. Geriatrics 33, 47-52.
31. Bush AL, Hyson RL (2006). Lithium increases Bcl-2 expression in chick cochlear nucleus and protects against deafferentation-induced cell death. Neuroscience 138, 1341-1349.
32. Cade J (1970). The story of lithium. In: Ayd F, Blackwell B (Eds.), Discoveries in Biological Psychiatry Philadelphia: Lippincott.
33. Cadotte DW, Xu B, Racine RJ, MacQueen GM, Wang JF, McEwen B, Young LT (2003). Chronic lithium treatment inhibits pilocarpine-induced mossy fiber sprouting in rat hippocampus. Neuropsychopharmacology 28, 1448-1453.
34. Calabrese JR, Goldberg JF, Ketter TA, Suppes T, Frye M, White R, Deveaugh-Geiss A, Thompson TR (2006). Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies. Biological Psychiatry 59, 1061-1064.
35. Cantor CH (1986). Encephalopathy with lithium and thioridazine in combination. Medical Journal of Australia 144, 164-165.
36. Casanova B, de Entrambasaguas M, Perla C, Gomez-Siurana E, Beneto A, Burguera JA (1996). Lithium-induced Creutzfeldt-Jakob syndrome. Clinical Neuropharmacology 19, 356-359.
37. Celano E, Tiraboschi E, Consogno E, D'Urso G, Mbakop MP, Gennarelli M, de Bartolomeis A, Racagni G, Popoli M (2003). Selective regulation of presynaptic calcium/calmodulin-dependent protein kinase II by psychotropic drugs. Biological Psychiatry 53, 442-449.
38. Centeno F, Mora A, Fuentes JM, Soler G, Claro E (1998). Partial lithium-associated protection against apoptosis induced by C2-ceramide in cerebellar granule neurons. Neuroreport 9, 4199-4203.
39. Chakrabarti S, Chand PK (2002). Lithium-induced tardive dystonia. Neurology India 50, 473-475.
40. Chalecka-Franaszek E, Chuang DM (1999). Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proceedings of the National Academy of Sciences USA 96, 8745-8750.
41. Chang YC, Lin HN, Deng HC (1990). Subclinical lithium neurotoxicity: correlation of neural conduction abnormalities and serum lithium level in manic-depressive patients with lithium treatment. Acta Neurologica Scandinavica 82, 82-86.
42. Chaudhry RP, Waters BG (1983). Lithium and carbamazepine interaction: possible neurotoxicity. Journal of Clinical Psychiatry 44, 30-31.
43. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK (2000). Enhancement of hippocampal neurogenesis by lithium. Journal of Neurochemistry 75, 1729-1734.
44. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH, Manji HK (1999). The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. Journal of Neurochemistry 72, 879-882.
45. Chen RW, Chuang DM (1999). Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. Journal of Biological Chemistry 274, 6039-6042.
46. Chen RW, Qin ZH, Ren M, Kanai H, Chalecka-Franaszek E, Leeds P, Chuang DM (2003). Regulation of c-Jun Nterminal kinase, p38 kinase and AP-1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium neuroprotection. Journal of Neurochemistry 84, 566-575.
47. Chuang DM (2004). Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Critical Reviews in Neurobiology 16, 83-90.
48. Chuang DM (2005). The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Annals of the NY Academy of Science 1053, 195-204.
49. Chuang DM, Chen RW, Chalecka-Franaszek E, Ren M, Hashimoto R, Senatorov V, Kanai H, Hough C, Hiroi T, Leeds P (2002). Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disorder 4, 129-136.
50. Cimarosti H, Rodnight R, Tavares A, Paiva R, Valentim L, Rocha E, Salbego C (2001). An investigation of the neuroprotective effect of lithium in organotypic slice cultures of rat hippocampus exposed to oxygen and glucose deprivation. Neuroscience Letters 315, 33-36.
51. Cipriani A, Pretty H, Hawton K, Geddes JR (2005). Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. American Journal of Psychiatry 162, 1805-1819.
52. + therapy and site of origin on cerebrospinal fluid beta-amyloid precursor protein derivatives. Biochemical Society Transactions 21, 242S.
53. Connemann BJ (2006). Lithium and suicidality revisited. American Journal of Psychiatry 163, 550 (author reply 550-551).
54. Cook LL (1999). Ventricular enlargement and the lithium/pilocarpine seizure model: possible explanation for agonistic behaviour. International Journal of Neuroscience 100, 117-123.
55. Corbella B, Vieta E (2003). Molecular targets of lithium action. Acta Neuropsychiatrica 15, 1-25.
56. De Ferrari GV, Chacon MA, Barria MI, Garrido JL, Godoy JA, Olivares G, Reyes AE, Alvarez A, Bronfman M, Inestrosa NC (2003). Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Molecular Psychiatry 8, 195-208.
57. Deng MZ, Chen GQ, Phillips MR (1990). Neuroleptic malignant syndrome in 12 of 9792 Chinese inpatients exposed to neuroleptics: a prospective study. American Journal of Psychiatry 147, 1149-1155.
58. Di Daniel E, Mudge AW, Maycox PR (2005). Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons. Bipolar Disorder 7, 33-41.
59. Dinan TG, Kohen D (1989). Tardive dyskinesia in bipolar affective disorder: relationship to lithium therapy. British Journal of Psychiatry 155, 55-57.
60. Dou H, Ellison B, Bradley J, Kasiyanov A, Poluektova LY, Xiong H, Maggirwar S, Dewhurst S, Gelbard HA, Gendelman HE (2005). Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. Journal of Neuroscience 25, 8375-8385.
61. Du F, Eid T, Lothman EW, Kohler C, Schwarcz R (1995). Preferential neuronal loss in layer III of the medial entorhinal cortex in rat models of temporal lobe epilepsy. Journal of Neuroscience 15, 6301-6313.
62. Dunn N, Holmes C, Mullee M (2005). Does lithium therapy protect against the onset of dementia? Alzheimer's Disease and Associated Disorders 19, 20-22.
63. Eisenstadter A, Seiser A, Brainin M (1989). Neurotoxicity in long-term lithium therapy: an electroneurographic study [in German]. Wiener Klinische Wochenschrift 101, 166-168.
64. Elizur A, Yeret A, Segal Z, Graff E (1982). Lithium and electrolytes plasma/RBC ratio and paradoxical lithium neurotoxicity. Progress in Neuropsychopharmacology and Biological Psychiatry 6, 235-241.
65. Emilien G, Maloteaux JM (1996). Lithium neurotoxicity at low therapeutic doses Hypotheses for causes and mechanism of action following a retrospective analysis of published case reports. Acta Neurologica Belgica 96, 281-293.
66. Epstein RS (1989). Wernicke's encephalopathy following lithium-induced diarrhea. American Journal of Psychiatry 146, 806-807.
67. Ereshefsky L, Rubin TN, Friedman S (1979). Treatment of tardive dyskinesia and mania with RBC lithium determinations. American Journal of Psychiatry 136, 570-573.
68. Evans DL, Garner BW (1979). Neurotoxicity at therapeutic lithium levels. American Journal of Psychiatry 136, 1481-1482.
69. Everall IP, Bell C, Mallory M, Langford D, Adame A, Rockestein E, Masliah E (2002). Lithium ameliorates HIV-gp120-mediated neurotoxicity. Molecular and Cellular Neuroscience 21, 493-501.
70. Faravelli C, Di Bernardo M, Ricca V, Benvenuti P, Bartelli M, Ronchi O (1999). Effects of chronic lithium treatment on the peripheral nervous system. Journal of Clinical Psychiatry 60, 306-310.
71. Fava S, Galizia AC (1995). Neuroleptic malignant syndrome and lithium carbonate. Journal of Psychiatry and Neuroscience 20, 305-306.
72. Fetzer J, Kader G, Danahy S (1981). Lithium encephalopathy: a clinical, psychiatric, and EEG evaluation. American Journal of Psychiatry 138, 1622-1623.
73. Finelli PF (1992). Drug-induced Creutzfeldt-Jakob like syndrome. Journal of Psychiatry and Neuroscience 17, 103-105.
74. Flint A (1993). Ageing as a risk factor for lithium neurotoxicity at therapeutic serum levels. British Journal of Psychiatry 163, 555-556.
75. Foti ME, Pies RW (1986). Lithium carbonate and tardive dyskinesia. Journal of Clinical Psychopharmacology 6, 325-326.
76. Fountoulakis KN, Vieta E, Sanchez-Moreno J, Kaprinis SG, Goikolea JM, Kaprinis GS (2005). Treatment guidelines for Bipolar Disorder: a critical review. Journal of Affective Disorders 86, 1-10.
77. Fujikawa DG (1995). Neuroprotective effect of ketamine administered after status epilepticus onset. Epilepsia 36, 186-195.
78. Fuller MA, Sajatovic M (1989). Neurotoxicity resulting from a combination of lithium and loxapine. Journal of Clinical Psychiatry 50, 187.
79. Gabuzda DH, Frankenburg FR (1987). Fever caused by lithium in a patient with neuroleptic malignant syndrome. Journal of Clinical Psychopharmacology 7, 283-284.
80. Gallinat J, Boetsch T, Padberg F, Hampel H, Herrmann WM, Hegerl U (2000). Is the EEG helpful in diagnosing and monitoring lithium intoxication? A case report and review of the literature. Pharmacopsychiatry 33, 169-173.
81. Gao XM, Fukamauchi F, Chuang DM (1993). Long-term biphasic effects of lithium treatment on phospholipase C-coupled M3-muscarinic acetylcholine receptors in cultured cerebellar granule cells. Neurochemistry International 22, 395-403.
82. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM (2004). Long-term lithium therapy for Bipolar Disorder: systematic review and meta-analysis of randomized controlled trials. American Journal of Psychiatry 161, 217-222.
83. Gelenberg AJ (1980). Tardive dyskinesia and lithium-associated nephropathy: are you liable? Journal of Clinical Psychiatry 41, 368-369.
84. George B, Kulkarni SK (1996). Protective effects of GABAergic drugs and other anticonvulsants in lithium-pilocarpine-induced status epilepticus. Methods and Findings in Experimental and Clinical Pharmacology 18, 335-340.
85. Ghadirian AM, Lehmann HE (1980). Acquired transient CNS hypersensitivity to lithium therapy. Canadian Journal of Psychiatry 25, 662-665.
86. Ghribi O, Herman MM, Spaulding NK, Savory J (2002). Lithium inhibits aluminum-induced apoptosis in rabbit hippocampus, by preventing cytochrome c translocation, Bcl-2 decrease, Bax elevation and caspase-3 activation. Journal of Neurochemistry 82, 137-145.
87. Ghribi O, Prammonjago P, Herman MM, Spaulding NK, Savory J (2003). Abeta(1-42)-induced JNK and ERK activation in rabbit hippocampus is differentially regulated by lithium but is not involved in the phosphorylation of tau. Brain Research: Molecular Brain Research 119, 201-206.
88. Goldman SA (1996a). Lithium and neuroleptics in combination: is there enhancement of neurotoxicity leading to permanent sequelae? Journal of Clinical Pharmacology 36, 951-962.
89. Goldman SA (1996b). Lithium and neuroleptics in combination: the spectrum of neurotoxicity [corrected]. Psychopharmacology Bulletin 32, 299-309.
90. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D (2003). Suicide risk in Bipolar Disorder during treatment with lithium and divalproex. Journal of the American Medical Association 290, 1467-1473.
91. Goodwin G, Vieta E (2005). Effective maintenance treatment - breaking the cycle of Bipolar Disorder. European Psychiatry 20, 365-371.
92. Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R (2004). A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. Journal of Clinical Psychiatry 65, 432-441.
93. Gould TD, Manji HK (2002). The Wnt signaling pathway in Bipolar Disorder. Neuroscientist 8, 497-511.
94. Gray NA, Zhou R, Du J, Moore GJ, Manji HK (2003). The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. Journal of Clinical Psychiatry 64 (Suppl. 5), 3-17.
95. Grimes CA, Jope RS (2001). The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Progress in Neurobiology 65, 391-426.
96. Gruenthal M (1984). Lithium attenuates the development of lesion-induced behavioral supersensitivity to apomorphine. Brain Research 306, 189-196.
97. Harada H, Sugiyama T, Suketa Y (1996). Characterization of inhibition by chronic treatment with lithium ion on nerve growth factor-induced neuronal differentiation of rat PC12 pheochromocytoma cells. Journal of Toxicology and Environmental Health 49, 197-206.
98. Harrison PJ (1999). The neuropathological effects of antipsychotic drugs. Schizophrenia Research 40, 87-99.
99. Harvey BH, Meyer CL, Gallichio VS, Manji HK (2002). Lithium salts in AIDS and AIDS-related dementia. Psychopharmacology Bulletin 36, 5-26.
100. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM (2002a). Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. Journal of Neurochemistry 80, 589-597.
101. Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang DM (2002b). Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43, 1173-1179.
102. Hay G, Simpson N (1982). Neurotoxicity associated with therapeutic serum lithium levels. Lancet 2, 160-161.
103. Hellweg R, Lang UE, Nagel M, Baumgartner A (2002). Subchronic treatment with lithium increases nerve growth factor content in distinct brain regions of adult rats. Molecular Psychiatry 7, 604-608.
104. Hellwig B, Hesslinger B, Walden J (1996). Acute brain syndrome after tapering off clozapine in clozapine-lithium combination. Progress in Neuropsychopharmacology and Biological Psychiatry 20, 179-183.
105. Hennion JP, el-Masri MA, Huff MO, el-Mailakh RS (2002). Evaluation of neuroprotection by lithium and valproic acid against ouabain-induced cell damage. Bipolar Disorder 4, 201-206.
106. Hong M, Chen DC, Klein PS, Lee VM (1997). Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. Journal of Biological Chemistry 272, 25326-25332.
107. Hongisto V, Smeds N, Brecht S, Herdegen T, Courtney MJ, Coffey ET (2003). Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. Molecular and Cellular Biology 23, 6027-6036.
108. James JF, Reilly E (1971). The electroencephalographic recording of short- and long-term lithium effect. South Medical Journal 64, 1322-1327.
109. Jefferson J, Greist J (2000). Lithium. In: Sadock B, Sadock V (Eds.), Comprehensive Textbook of Psychiatry (pp. 2377-2390) Philadelphia: Lippincott Williams and Wilkins.
110. Jin N, Kovacs AD, Sui Z, Dewhurst S, Maggirwar SB (2005). Opposite effects of lithium and valproic acid on trophic factor deprivation-induced glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death. Neuropharmacology 48, 576-583.
111. Johnson GF (1976). Lithium neurotoxicity. Australian and New Zealand Journal of Psychiatry 10, 33-38.
112. Jope RS (1999). Anti-bipolar therapy: mechanism of action of lithium. Molecular Psychiatry 4, 117-128.
113. Jope RS, Bijur GN (2002). Mood stabilizers, glycogen synthase kinase-3beta and cell survival. Molecular Psychiatry 7 (Suppl. 1), S35-45.
114. Jorda EG, Verdaguer E, Canudas AM, Jimenez A, Garcia de Arriba S, Allgaier C, Pallas M, Camins A (2005). Implication of cyclin-dependent kinase 5 in the neuroprotective properties of lithium. Neuroscience 134, 1001-1011.
115. Jorda EG, Verdaguer E, Morano A, Jimenez A, Canudas AM, Camins A, Pallas M (2004). Lithium prevents colchicine-induced apoptosis in rat cerebellar granule neurons. Bipolar Disorder 6, 144-149.
116. Kang HJ, Noh JS, Bae YS, Gwag BJ (2003). Calcium-dependent prevention of neuronal apoptosis by lithium ion: essential role of phosphoinositide 3-kinase and phospholipase Cgamma. Molecular Pharmacology 64, 228-234.
117. Keitner GI, Rahman S (1984). Reversible neurotoxicity with combined lithium-haloperidol administration. Journal of Clinical Psychopharmacology 4, 104-105.
118. Keltner NL (1997). Catastrophic consequences secondary to psychotropic drugs, Part 1. Journal of Psychosocical Nursing and Mental Health Services 44, 41-45.
119. Kemperman CJ, Gerdes JH, De Rooij J, Vencken LM (1989). Reversible lithium neurotoxicity at normal serum level may refer to intracranial pathology. Journal of Neurology Neurosurgery and Psychiatry 52, 679-680.
120. Kemperman CJ, Notermans SL (1989). Creutzfeld-Jacob like syndrome due to lithium toxicity. Journal of Neurology Neurosurgery and Psychiatry 52, 291.
121. Kessel JB, Verghese C, Simpson GM (1992). Neurotoxicity related to lithium and neuroleptic combinations? A retrospective review. Journal of Psychiatry and Neuroscience 17, 28-30.
122. Kikyo H, Furukawa T (1999). Creutzfeldt-Jakob-like syndrome induced by lithium, levomepromazine, and phenobarbitone. Journal of Neurology Neurosurgery and Psychiatry 66, 802-803.
123. Koehler PJ, Mirandolle JF (1988). Neuroleptic malignant-like syndrome and lithium. Lancet 2, 1499-1500.
124. Kopnisky KL, Chalecka-Franaszek E, Gonzalez-Zulueta M, Chuang DM (2003). Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increasing MEK activities. Neuroscience 116, 425-435.
125. 3H]spiroperidol binding sites. Brain Research 267, 301-311.
126. Kumar R, Deb JK, Sinha VK (1999). Lithium neurotoxicity at therapeutic level - a case report. Journal of Indian Medical Association 97, 473-474.
127. Lagace DC, Eisch AJ (2005). Mood-stabilizing drugs: are their neuroprotective aspects clinically relevant? Psychiatric Clinics of North America 28, 399-414.
128. Lambreva E, Vecellio M, Wieser HG, Buddeberg C (2005). Neurotoxic encephalopathy caused by neuroleptics and lithium [in German]. Nervenarzt 76 (Suppl. 5), 756-759.
129. Lang EJ, Davis SM (2002). Lithium neurotoxicity: the development of irreversible neurological impairment despite standard monitoring of serum lithium levels. Journal of Clinical Neuroscience 9, 308-309.
130. Lazarus A (1994). Tardive dyskinesia-like syndrome associated with lithium and carbamazepine. Journal of Clinical Psychopharmacology 14, 146-147.
131. Ledoux JM (2003). Features of the comparative pharmacokinetics of lithium; a potential application of its use in livestock farming. Medical Hypotheses 61, 278-281.
132. Lee SH, Yang YY (1999). Reversible neurotoxicity induced by a combination of clozapine and lithium: a case report. Zhonghua Yi Xue Za Zhi (Taipei) 62, 184-187.
133. Lenox R, Frazer A (2002). Mechanism of action of antidepressants and mood stabilizers. In: Davis K, Charney D, Coyle J, Nemeroff C (Eds.), Neuropsychopharmacology: The Fifth Generation of Progress (pp. 1139-1163) Philadelphia: Lippincott Williams and Wilkins.
134. Li R, El-Mallahk RS (2000). A novel evidence of different mechanisms of lithium and valproate neuroprotective action on human SY5Y neuroblastoma cells: caspase-3 dependency. Neuroscience Letters 294, 147-150.
135. Li X, Bijur GN, Jope RS (2002a). Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disorder 4, 137-144.
136. Li X, Ketter TA, Frye MA (2002b). Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of Bipolar Disorders? Journal of Affective Disorders 69, 1-14.
137. Licht RW, Larsen JO, Smith D, Braendgaard H (1994). Effect of chronic lithium treatment with or without haloperidol on number and sizes of neurons in rat neocortex. Psychopharmacology (Berlin) 115, 371-374.
138. Licht RW, Larsen JO, Smith D, Braendgaard H (2003). Chronic lithium treatment with or without haloperidol fails to affect the morphology of the rat cerebellum. European Neuropsychopharmacology 13, 173-176.
139. Licht RW, Smith D, Braendgaard H (1997). The effect of chronic lithium treatment on the calibre of axons and nerve fibres in the rat sural nerve. European Neuropsychopharmacology 7, 95-98.
140. Lieb J (1980). Linoleic acid in the treatment of lithium toxicity and familial tremor. Prostaglandins and Medicine 4, 275-279.
141. Lu R, Song L, Jope RS (1999). Lithium attenuates p53 levels in human neuroblastoma SH-SY5Y cells. Neuroreport 10, 1123-1125.
142. Ma J, Zhang GY (2003). Lithium reduced N-methyl-Daspartate receptor subunit 2A tyrosine phosphorylation and its interactions with Src and Fyn mediated by PSD-95 in rat hippocampus following cerebral ischemia. Neuroscience Letters 348, 185-189.
143. Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S (1999). HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. Journal of Neurochemistry 73, 578-586.
144. Mani J, Tandel SV, Shah PU Karnad DR (1996). Prolonged neurological sequelae after combination treatment with lithium and antipsychotic drugs. Journal of Neurology Neurosurgery and Psychiatry 60, 350-351.
145. Manji H, Moore GJ (2001). Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers. British Journal of Psychiatry 178, (Suppl. 41), S107-119.
146. Manji HK, Duman RS (2001). Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacology Bulletin 35, 5-49.
147. Manji HK, Moore GJ, Chen G (1999). Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biological Psychiatry 46, 929-940.
148. Manji HK, Moore GJ, Chen G (2000a). Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. Journal of Clinical Psychiatry 61 (Suppl. 9), 82-96.
149. Manji HK, Moore GJ, Rajkowska G, Chen G (2000b). Neuroplasticity and cellular resilience in mood disorders. Molecular Psychiatry 5, 578-593.
150. Mann SC, Greenstein RA, Eilers R (1983). Early onset of severe dyskinesia following lithium-haloperidol treatment. American Journal of Psychiatry 140, 1385-1386.
151. McLaren KD, Marangell LB (2004). Special considerations in the treatment of patients with Bipolar Disorder and medical co-morbidities. Annals of General Hospital Psychiatry 3, 7.
152. Meinardi JR, Donders SH (1997). Nephrogenic diabetes insipidus in a lethargic lithium-treated patient. The Netherlands Journal of Medicine 50, 105-109.
153. Miller F, Menninger J (1987a). Correlation of neuroleptic dose and neurotoxicity in patients given lithium and a neuroleptic. Hospital and Community Psychiatry 38, 1219-1221.
154. Miller F, Menninger J (1987b). Lithium-neuroleptic neurotoxicity is dose dependent. Journal of Clinical Psychopharmacology 7, 89-91.
155. Miller F, Menninger J, Whitcup SM (1986). Lithiumneuroleptic neurotoxicity in the elderly bipolar patient. Journal of Clinical Psychopharmacology 6, 176-178.
156. Moore GJ, Bebchuk JM, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds IB, Faulk MW, Koch S, Glitz DA, Jolkovsky L, Manji HK (2000a). Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2′s neurotrophic effects? Biological Psychiatry 48, 1-8.
157. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK, Menji HK (2000b). Lithium-induced increase in human brain grey matter. Lancet 356, 1241-1242.
158. +. European Journal of Biochemistry 266, 886-891.
159. Mora A, Sabio G, Alonso JC, Soler G, Centeno F (2002a). Different dependence of lithium and valproate on PI3K/ PKB pathway. Bipolar Disorder 4, 195-200.
160. Mora A, Sabio G, Risco AM, Cuenda A, Alonso JC, Soler G, Centeno F (2002b). Lithium blocks the PKB and GSK3 dephosphorylation induced by ceramide through protein phosphatase-2A. Cell Signal 14, 557-562.
161. Morgenstern H, Glazer WM, Gibowski LD, Holmberg S (1987). Predictors of tardive dyskinesia: results of a cross-sectional study in an outpatient population. Journal of Chronic Disease 40, 319-327.
162. Mortimer AM, Shepherd CJ, Rymer M, Burrows A (2005). Primary care use of antipsychotic drugs: an audit and intervention study. Annals of General Psychiatry 4, 18.
163. Moscovich DG (1993). Lithium neurotoxicity at normal therapeutic levels. British Journal of Psychiatry 163, 410-412.
164. Munoz-Montano JR, Moreno FJ, Avila J, Diaz-Nido J (1997). Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Letters 411, 183-188.
165. Muthane UB, Prasad BN, Vasanth A, Satishchandra P (2000). Tardive Parkinsonism, orofacial dyskinesia and akathisia following brief exposure to lithium carbonate. Journal of Neurological Science 176, 78-79.
166. Naramoto A, Koizumi N, Itoh N, Shigematsu H (1993). An autopsy case of cerebellar degeneration following lithium intoxication with neuroleptic malignant syndrome. Acta Pathologica Japonica 43, 55-58.
167. Nonaka S, Chuang DM (1998). Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 9, 2081-2084.
168. Nonaka S, Katsube N, Chuang DM (1998). Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine. Journal of Pharmacology and Experimental Therapeutics 286, 539-547.
169. Normann C, Brandt C, Berger M, Walden J (1998). Delirium and persistent dyskinesia induced by a lithium-neuroleptic interaction. Pharmacopsychiatry 31, 201-204.
170. Oakley PW, Whyte IM, Carter GL (2001). Lithium toxicity: an iatrogenic problem in susceptible individuals. Australian and New Zealand Journal of Psychiatry 35, 833-840.
171. Palacino JJ, Murphy MP, Murayama O, Iwasaki K, Fujiwara M, Takashima A, Golde TE, Wolozin B (2001). Presenilin 1 regulates beta-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion. Journal of Biological Chemistry 276, 38563-38569.
172. Pandey GN, Goel I, Davis JM (1979). Effect of neuroleptic drugs on lithium uptake by the human erythrocyte. Clinical Pharmacology and Therapeutics 26, 96-102.
173. Paoletti AM, Piccirilli S, Costa N, Rotiroti D, Bagetta G, Nistico G (1998). Systemic administration of N omega-nitro-L-arginine methyl ester and indomethacin reduces the elevation of brain PGE2 content and prevents seizures and hippocampal damage evoked by LiCl and tacrine in rat. Experimental Neurology 149, 349-355.
174. Pascual T, Gonzalez JL (1995). A protective effect of lithium on rat behaviour altered by ibotenic acid lesions of the basal forebrain cholinergic system. Brain Research 695, 289-292.
175. Pazdernik TL, Emerson MR (2001). Soman-induced seizures: limbic activity, oxidative stress and neuroprotective proteins. Journal of Applied Toxicology 21 (Suppl. 1), S87-94.
176. Perenyi A, Szucs R, Frecska E (1984). Tardive dyskinesia in patients receiving lithium maintenance therapy. Biological Psychiatry 19, 1573-1578.
177. Perez M, Hernandez F, Lim F, Diaz-Nido J, Avila J (2003). Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. Journal of Alzheimers Disease 5, 301-308.
178. Persinger MA, Peredery O, Desjardins D, Eastman A (1998). Ventricular dilation over several weeks following induction of excitotoxic (systemic lithium/pilocarpine) lesions: potential role of damage to the substantia nigra reticulata. International Journal of Neuroscience 94, 63-74.
179. Petrini M, Vaglini F, Cervetti G, Cavalletti M, Sartucci F, Murri L, Corsini GU (1999). Is lithium able to reverse neurological damage induced by vinca alkaloids? (Short communication). Journal of Neural Transmission 106, 569-575.
180. Petterson U (1977). Manic-depressive illness. A clinical, social and genetic study. Acta Psychiatrica Scandinavica (Suppl.), 269, 1-93.
181. Phiel CJ, Wilson CA, Lee VM, Klein PS (2003). GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423, 435-439.
182. Pomara N, Banay-Schwartz M, Block R, Stanley M, Gershon S (1983). Elevation of RBC glycine and choline levels in geriatric patients treated with lithium. American Journal of Psychiatry 140, 911-913.
183. Prakash R, Kelwala S, Ban TA (1982a). Neurotoxicity in patients with schizophrenia during lithium therapy. Comprehensive Psychiatry 23, 271-273.
184. Prakash R, Kelwala S, Ban TA (1982b). Neurotoxicity with combined administration of lithium and a neuroleptic. Comprehensive Psychiatry 23, 567-571.
185. Prettyman R (1994). Lithium neurotoxicity at subtherapeutic serum levels. British Journal of Psychiatry 164, 123.
186. Price WA, Giannini AJ (1986). Neurotoxicity caused by lithium-verapamil synergism. Journal of Clinical Pharmacology 26, 717-719.
187. Primavera A, Brusa G, Poeta MG (1989). A Creutzfeldt-Jakob like syndrome due to lithium toxicity. Journal of Neurology Neurosurgery and Psychiatry 52, 423.
188. Reed SM, Wise MG, Timmerman I (1989). Choreoathetosis: a sign of lithium toxicity. Journal of Neuropsychiatry and Clinical Neuroscience 1, 57-60.
189. Ren M, Senatorov VV, Chen RW, Chuang DM (2003). Postinsult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proceedings of the National Academy of Science USA 100, 6210-6215.
190. Rigoulot MA, Koning E, Ferrandon A, Nehlig A (2004). Neuroprotective effect of topiramate in the lithiumpilocarpine model of epilepsy. Journal of Pharmacology and Experimental Therapeutics 308, 787-795.
191. Rigoulot MA, Leroy C, Koning E, Ferrandon A, Nehlig A (2003). Prolonged low-dose caffeine exposure protects against hippocampal damage but not against the occurrence of epilepsy in the lithium-pilocarpine model in the rat. Epilepsia 44, 529-535.
192. Roch C, Leroy C, Nehlig A, Namer IJ (2002). Magnetic resonance imaging in the study of the lithium-pilocarpine model of temporal lobe epilepsy in adult rats. Epilepsia 43, 325-335.
193. Rocha E, Achaval M, Santos P, Rodnight R (1998). Lithium treatment causes gliosis and modifies the morphology of hippocampal astrocytes in rats. Neuroreport 9, 3971-3974.
194. Rocha E, Rodnight R (1994). Chronic administration of lithium chloride increases immunodetectable glial fibrillary acidic protein in the rat hippocampus. Journal of Neurochemistry 63, 1582-1584.
195. Rowe MK, Chuang DM (2004). Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Review in Molecular Medicine 6, 1-18.
196. Rush J, Mendels J (1975). Effects of lithium chloride on muricidal behavior in rats. Pharmacology Biochemistry and Behavior 3, 795-797.
197. Sandyk R, Hurwitz MD (1983). Toxic irreversible encephalopathy induced by lithium carbonate and haloperidol. A report of 2 cases. South Africa Medical Journal 64, 875-876.
198. Santi SA, Cook LL, Persinger MA, O'Connor RP (2001). Normal spatial memory following postseizure treatment with ketamine: selective damage attenuates memory deficits in brain-damaged rodents. International Journal of Neuroscience 107, 63-75.
199. Saran A, Addy O, Foliart RH, Schubert DS, Halaris A (1989). Electroencephalographic changes and other indices of neurotoxicity with haloperidol-lithium therapy. Neuropsychobiology 20, 152-157.
200. Sassi RB, Soares JC (2001). Emerging therapeutic targets in bipolar mood disorder. Expert Opinion on Therapeutic Targets 5, 587-599.
201. Savory J, Herman MM, Ghribi O (2003). Intracellular mechanisms underlying aluminum-induced apoptosis in rabbit brain. Journal of Inorganic Biochemistry 97, 151-154.
202. Schou M (1997). Forty years of lithium treatment. Archives of General Psychiatry 54, 9.
203. Senatorov VV, Ren M, Kanai H, Wei H, Chuang DM (2004). Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease. Molecular Psychiatry 9, 371-385.
204. Setta F, Manto MU, Jacquy J, Hildebrand J, Godaux E, Linkowski P (1998). Kinematics of fast wrist movements in manic-depressive illness chronically treated with lithium carbonate. Neurological Research 20, 320-326.
205. Shao L, Young LT, Wang JF (2005). Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biological Psychiatry 58, 879-884.
206. Sheean GL (1991). Lithium neurotoxicity. Clinical and Experimental Neurology 28, 112-127.
207. Shulman KI, Sykora K, Gill S, Mamdani M, Bronskill S, Wodchis WP, Anderson G, Rochon P (2005). Incidence of delirium in older adults newly prescribed lithium or valproate: a population-based cohort study. Journal of Clinical Psychiatry 66, 424-427.
208. Silverstone PH, Bell EC, Willson MC, Dave S, Wilman AH (2005). Lithium alters brain activation in Bipolar Disorder in a task- and state-dependent manner: an fMRI study. Annals of General Psychiatry 4, 14.
209. Slonim R, McLarty B (1985). Sixth cranial nerve palsy - unusual presenting symptom of lithium toxicity? Canadian Journal of Psychiatry 30, 443-444.
210. Smith D, Keane P, Donovan J, Malone K, McKenna TJ (2003). Lithium encephalopathy. Journal of the Royal Society of Medicine 96, 590-591.
211. Smith SJ, Kocen RS (1988). A Creutzfeldt-Jakob like syndrome due to lithium toxicity. Journal of Neurology Neurosurgery and Psychiatry 51, 120-123.
212. Spring G, Frankel M (1981). New data on lithium and haloperidol incompatibility. American Journal of Psychiatry 138, 818-821.
213. Spring GK (1979). Neurotoxicity with combined use of lithium and thioridazine. Journal of Clinical Psychiatry 40, 135-138.
214. Sternbach H, Jordan S (1990). Lithium-associated tardive dyskinesia. Journal of Clinical Psychopharmacology 10, 143-144.
215. Stewart JT, Williams LS (2000). A case of lithium-induced asterixis. Journal of the American Geriatrics Society 48, 457.
216. Stoothoff WH, Johnson GV (2001). Hyperosmotic stressinduced apoptosis and tau phosphorylation in human neuroblastoma cells. Journal of Neuroscience Research 65, 573-582.
217. Strayhorn Jr. JM, Nash JL (1977). Severe neurotoxicity despite 'therapeutic' serum lithium levels. Diseases of the Nervous System 38, 107-111.
218. Struve FA (1987). Lithium-specific pathological electroencephalographic changes: a successful replication of earlier investigative results. Clinical Electroencephalography 18, 46-53.
219. Su Y, Ryder J, Li B, Wu X, Fox N, Solenberg P, Brune K, Paul S, Zhou Y, Liu F, Ni B (2004). Lithium, a common drug for Bipolar Disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 43, 6899-6908.
220. Swartz CM (2001). Olanzapine-lithium encephalopathy. Psychosomatics 42, 370.
221. Thornton WE, Pray BJ (1975). Lithium intoxication: a report of two cases. Canadian Psychiatric Association Journal 20, 281-282.
222. Tseng WP, Lin-Shiau SY (2002). Long-term lithium treatment prevents neurotoxic effects of beta-bungarotoxin in primary cultured neurons. Journal of Neuroscience Research 69, 633-641.
223. Verdoux H, Bourgeois ML (1990). A case of lithium neurotoxicity with irreversible cerebellar syndrome. Journal of Nervous and Mental Disease 178, 761-762.
224. Wada A, Yokoo H, Yanagita T, Kobayashi H (2005). Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. Journal of Pharmacological Science 99, 307-321.
225. Walton NY, Treiman DM (1991). Motor and electroencephalographic response of refractory experimental status epilepticus in rats to treatment with MK-801, diazepam, or MK-801 plus diazepam. Brain Research 553, 97-104.
226. Wei H, Leeds PR, Qian Y, Wei W, Chen R, Chuang D (2000). beta-amyloid peptide-induced death of PC 12 cells and cerebellar granule cell neurons is inhibited by long-term lithium treatment. European Journal of Pharmacology 392, 117-123.
227. Wei H, Qin ZH, Senatorov VV, Wei W, Wang Y, Qian Y, Chuang DM (2001). Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 106, 603-612.
228. West AP, Meltzer HY (1979). Paradoxical lithium neurotoxicity: a report of five cases and a hypothesis about risk for neurotoxicity. American Journal of Psychiatry 136, 963-966.
229. Wilczynski NL, Haynes RB (2006). Optimal search strategies for identifying mental health content in MEDLINE: an analytic survey. Annals of General Psychiatry 5, 4.
230. Wilot LC, Da Silva RS, Ferreira OJ, Bonan CD, Sarkis JJ, Rocha E, Battastini AM (2004). Chronic treatment with lithium increases the ecto-nucleotidase activities in rat hippocampal synatosomes. Neuroscience Letters 368, 167-170.
231. Wood G, Young L (2004). Stress-induced structural remodeling in hippocampus: prevention by lithium treatment. Proceedings of the National Academy of Sciences USA 101, 3973-3978.
232. Wright BA, Jarrett DB (1991). Lithium and calcium channel blockers: possible neurotoxicity. Biological Psychiatry 30, 635-636.
233. Wu RH, O'Donnell T, Ulrich M, Asghar SJ, Hanstock CC, Silverstone PH (2004). Brain choline concentrations may not be altered in euthymic Bipolar Disorder patients chronically treated with either lithium or sodium valproate. Annals of General Hospital Psychiatry 3, 13.
234. Xu J, Culman J, Blume A, Brecht S, Gohlke P (2003). Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death. Stroke 34, 1287-1292.
235. Yao CJ, Lin CW, Lin-Shiau SY (1999). Altered intracellular calcium level in association with neuronal death induced by lithium chloride. Journal of the Formosan Medical Association 98, 820-826.
236. Yassa R (1986). A case of lithium-chlorpromazine interaction. Journal of Clinical Psychiatry 47, 90-91.
237. Youdim MB, Arraf Z (2004). Prevention of MPTP (N-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 46, 1130-1140.